Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $560.00 Price Target at UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by research analysts at UBS Group from $633.00 to $560.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s target price would suggest a potential upside of 13.54% from the stock’s […]

Jun 7, 2025 - 07:02

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by research analysts at UBS Group from $633.00 to $560.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s target price would suggest a potential upside of 13.54% from the stock’s […]